AAREYDRUGS Stock Overview
Manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Aarey Drugs & Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹53.98 |
| 52 Week High | ₹74.80 |
| 52 Week Low | ₹31.35 |
| Beta | 0.38 |
| 1 Month Change | -3.71% |
| 3 Month Change | 27.25% |
| 1 Year Change | 5.84% |
| 3 Year Change | 34.95% |
| 5 Year Change | n/a |
| Change since IPO | 24.52% |
Recent News & Updates
Recent updates
Insufficient Growth At Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Hampers Share Price
Apr 03
Earnings Not Telling The Story For Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) After Shares Rise 46%
Aug 30Aarey Drugs & Pharmaceuticals Limited's (NSE:AAREYDRUGS) Shares May Have Run Too Fast Too Soon
Jul 16Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Apr 15Aarey Drugs & Pharmaceuticals (NSE:AAREYDRUGS) Has A Pretty Healthy Balance Sheet
Mar 22What Aarey Drugs & Pharmaceuticals Limited's (NSE:AAREYDRUGS) P/E Is Not Telling You
Dec 30Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Shares Fly 25% But Investors Aren't Buying For Growth
Dec 29Calculating The Fair Value Of Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS)
Aug 20Shareholder Returns
| AAREYDRUGS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.1% | 2.7% | 6.3% |
| 1Y | 5.8% | 12.1% | 4.0% |
Return vs Industry: AAREYDRUGS underperformed the Indian Pharmaceuticals industry which returned 12.1% over the past year.
Return vs Market: AAREYDRUGS exceeded the Indian Market which returned 4% over the past year.
Price Volatility
| AAREYDRUGS volatility | |
|---|---|
| AAREYDRUGS Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: AAREYDRUGS's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: AAREYDRUGS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Mihir Ghatalia | www.aareydrugs.com |
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company provides mono methyl and die methyl urea, ortho para nitro anisole, 2 bromomethyl 1, and 3 dioxalane and uracile, as well as active pharma ingredients, such as metformin HCL, mefenamic acid, and doxophylline. It also offers chemicals and solvents, including aromatic chemicals, chemical acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, and chlorinated solvents, as well as industrial alchols, ketones, amines, oleochemicals, intermediates, olefines, phosphates, fertilizers, monomers, and chemicals.
Aarey Drugs & Pharmaceuticals Limited Fundamentals Summary
| AAREYDRUGS fundamental statistics | |
|---|---|
| Market cap | ₹1.52b |
| Earnings (TTM) | ₹57.06m |
| Revenue (TTM) | ₹5.76b |
26.6x
P/E Ratio0.3x
P/S RatioIs AAREYDRUGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAREYDRUGS income statement (TTM) | |
|---|---|
| Revenue | ₹5.76b |
| Cost of Revenue | ₹5.59b |
| Gross Profit | ₹172.17m |
| Other Expenses | ₹115.12m |
| Earnings | ₹57.06m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 30, 2025
| Earnings per share (EPS) | 2.04 |
| Gross Margin | 2.99% |
| Net Profit Margin | 0.99% |
| Debt/Equity Ratio | 28.5% |
How did AAREYDRUGS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 09:51 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aarey Drugs & Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |